Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P02768

UPID:
ALBU_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P02768; E7ESS9; O95574; P04277; Q13140; Q645G4; Q68DN5; Q6UXK4; Q86YG0; Q8IUK7; Q9P157; Q9P1I7; Q9UHS3; Q9UJZ0

BACKGROUND:
The protein Albumin serves as a major transporter of substances like fatty acids, hormones, and minerals in the bloodstream. It is essential for regulating blood volume and pressure by controlling the colloidal osmotic pressure. Albumin's ability to bind to metals such as zinc and calcium underscores its role in mineral homeostasis. Its interaction with bacterial siderophores also points to a potential role in immune defense by limiting iron availability to pathogens.

THERAPEUTIC SIGNIFICANCE:
The critical role of Albumin in diseases like familial dysalbuminemic hyperthyroxinemia and Analbuminemia reveals its potential as a therapeutic target. These disorders, linked to albumin gene variants, affect thyroid hormone levels and serum albumin concentration, respectively. Exploring Albumin's multifaceted functions could lead to novel interventions for these and possibly other related conditions, emphasizing the importance of continued research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.